Barclays' Head of US Biopharma Equity Research Emily Field told CNBC Monday August 24, 2026 that the biotech mergers and acquisitions (M&A) freeze is over. Key drivers cited: capital markets reopening (drug startup IPOs have raised roughly $6 billion year-to-date, more than the combined total of the prior four years by this point), large-cap pharma buyers committing to more deals following a multi-year period of caution, and fresh oncology data extending the sector's value proposition beyond the weight-loss drug narrative that dominated 2024-2025. The commentary follows a rapid acceleration of biotech M&A activity through August: Samsung Biologics' pending $1.8 billion PolyPeptide Group AG all-cash tender offer (formal prospectus expected end of August), BioMarin Pharmaceutical's Alesta Therapeutics acquisition for ALE1 program (August 21), Tolerance Bio's $260 million exclusive license from NeoImmuneTech for NT-I7 (efineptakin alfa, long-acting IL-7 fusion protein, August 20), LEO Pharma's dersimelagon (MC1R agonist) acquisition from Mitsubishi Tanabe (August 18), and Hanmi Pharm's up-to-$2.3 billion HM17321 UCN2 licensing to Genentech announced the same Monday. The pattern suggests the M&A environment is now supportive for both mid-cap platform buyers (Samsung Biologics, LEO Pharma, BioMarin) and mega-cap oncology and metabolic-disease buyers (Roche/Genentech, Bristol Myers Squibb, Merck, Eli Lilly) actively pursuing deals. Field's commentary also notes that oncology data (particularly the Merck-Moderna intismeran Phase 3 melanoma win and Gilead Trodelvy+Keytruda EU authorization from the same week) has substantially reset investor expectations about the sector beyond obesity.
Post-PCAC analyst coverage of Hims & Hers Health (NYSE: HIMS) split on the July 23-24 Pharmacy Compounding Advisory Committee (PCAC) 6-of-7 outcome. BofA Securities raised its price target to $36 on the peptide-compounding opportunity, and Canaccord Genuity raised to $40, both citing the July 23-24 PCAC vote and the Hims & Hers acquired California peptide manufacturing facility. Analysts estimate the four Day-1 recommended peptides (BPC-157, KPV, TB-500, MOTS-c) could generate approximately $440 million in Hims & Hers sales by 2027 if the FDA follows through with 503A rulemaking. Truist Securities held at $23 citing the 6-18 month FDA rulemaking timeline and continued uninsured-patient exposure. Barclays sits at $39 (Novo Nordisk partnership thesis). The peptide catalyst lift is tempered by the advisory-vote nature of the PCAC outcome: compounding pharmacies still cannot legally prepare BPC-157, KPV, TB-500, MOTS-c, Semax, or Epitalon under Section 503A today because none of the six substances are on the 503A Bulks List. FDA rulemaking to add each substance takes 6-18 months from the date the agency decides to act. Hims shares closed near $28.50 last week after briefly rallying above $35 on the initial vote outcome.
Analyst dispersion around Hims & Hers Health (NYSE: HIMS) widened this week following the FDA career-staff briefing documents released June 29-30 concluding all seven PCAC peptides have insufficient evidence for 503A bulks-list inclusion. The four fresh price targets span nearly two-to-one: Truist Securities reiterated a Hold rating with a $23 price target, citing near-term-performance strength tempered by uncertainty around peptide-compounding regulation. BofA Securities raised its price target to $36 from $25 while maintaining Neutral, noting the FDA update is negative for the company's peptide-optionality narrative but not the core weight-loss business. Barclays' Glen Santangelo raised to $39 from $29 while maintaining Overweight, crediting improvements from the renewed Novo Nordisk partnership. Canaccord's Maria Ripps raised to $40 from $32 while maintaining Buy, citing the company's transition from compounded to branded weight-loss drugs. The 74% spread from lowest to highest target reflects analyst disagreement about how much of the Hims growth story now runs through peptide optionality versus branded-GLP-1 rails.
Hims & Hers Health (NYSE: HIMS) is up roughly 25% in June 2026 on multiple converging investor signals heading into the final week of the month. Novo Nordisk leadership called Hims one of its most 'voluminous' telehealth partners on a recent earnings call, validating the March 2026 branded-supply pact that ended the prior compounded-GLP-1 litigation. Leerink reiterated its Market Perform rating ahead of the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) meeting, framing peptides as the company's next major product category and a key 2027+ growth driver. Barclays raised its price target to $39 from $29 on June 17 with an Overweight rating. CEO Andrew Dudum confirmed Oura Ring integration is 'coming soon,' adding wearable connectivity to the platform. The Hims GLP-1 subscription stack now runs $39 for the first month and $149 monthly thereafter (excluding medication costs), with branded Novo Wegovy injections and pills available alongside the company's owned California compounding-pharmacy capacity for the post-PCAC peptide expansion. The convergence of investor signals (analyst PT raises, Novo validation, PCAC catalyst, wearable integration) makes HIMS one of the most-watched names in the obesity-and-longevity telehealth space heading into Q3 2026.
Barclays raised its price target on Hims & Hers Health (NYSE: HIMS) to $39 from $29 on June 17, citing improved customer-momentum signals from alternative data since the March 9 Novo Nordisk collaboration announcement and the upcoming peptide-catalyst opportunity tied to the July 23-24 PCAC meeting. The firm maintained an Overweight rating; the $39 target implies roughly 21% upside from the prior close. HIMS gained about 6% on the day. Leerink reiterated Market Perform with a $25 PT ahead of the same PCAC meeting, framing potential PCAC approval as an upside catalyst for Hims' growth outlook beyond 2027. Hims acquired a California peptide manufacturing facility in 2025 and added in-house lab testing capacity ahead of the regulatory window.
Wall Street's mid-May Lilly outlook is firmly bullish. Barclays analyst Emily Field raised her LLY price target to $1,400 from $1,350 (Overweight) citing tirzepatide momentum and the easing concerns around Foundayo's launch trajectory. Cantor Fitzgerald lifted its target to $1,230 with an Overweight rating on Mounjaro demand and Foundayo PBM coverage activation. Motley Fool's May 17 commentary settled on $1,085 with a buy rating and 70% confidence, citing the company's raised 2026 guidance ($82-85B revenue) after one quarter as the deciding factor. The combined analyst view: Q1's $19.8B revenue print (+55.5% YoY) and Mounjaro's $8.66B quarter — which displaced Keytruda as the world's #1 best-selling drug — anchor the upside case while Foundayo's Week 5 acceleration removes the launch-trajectory overhang.
Barclays analyst Emily Field raised her price target on Eli Lilly to $1,400 from $1,350 May 5 and reiterated an Overweight rating, citing tirzepatide momentum continuing to outpace the GLP-1 class and easing concerns around the Foundayo launch trajectory. LLY stock had recovered roughly 11% off the May 4 Foundayo FAERS-driven dip to about $966 by mid-week. Barclays simultaneously trimmed its 2026 Foundayo revenue estimate to approximately $1B (vs. ~$1.4B consensus) on the early IQVIA gap to Wegovy pill, but the higher headline target reflects confidence that Mounjaro and Zepbound's volume growth more than absorbs Foundayo's slower start.